These data suggested that TNFR1 aggravated, whereas TNFR2 alleviated TAC-induced cardiac hypertrophy, dysfunction, and production of pro-inflammatory cytokines. This evidence concerns the gene TNFRSF1A and cardiac hypertrophy.